查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1546208

子宫癌治疗与诊断的全球市场

Uterine Cancer Therapeutics and Diagnostics
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 173 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球子宫癌药物和诊断市场预计将达到 282 亿美元

子宫癌药物和诊断的全球市场预计 2023 年为 214 亿美元，预计到 2030 年将达到 282 亿美元，在 2023-2030 年分析期间复合年增长率为 4.0%。子宫内膜癌治疗和诊断是本报告分析的细分市场之一，预计复合年增长率为 4.9%，到分析期结束时将达到 190 亿美元。在分析期间，子宫肉瘤治疗和诊断领域的复合年增长率估计为 2.4%。

美国市场预估57亿美元，中国预估年复合成长率7.5%

到 2023 年，美国子宫癌药物和诊断市场预计将达到 57 亿美元。中国作为世界第二大经济体，预计2030年市场规模将达64亿美元，2023-2030年分析期间复合年增长率为7.5%。其他值得注意的区域市场包括日本和加拿大，在分析期间预计复合年增长率分别为 1.3% 和 4.6%。在欧洲，德国的复合年增长率预计为 1.7%。

全球子宫癌治疗和诊断市场 - 主要趋势和驱动因素总结

为什么子宫内膜癌的检测和治疗很重要？

子宫内膜癌是影响女性最常见的癌症之一，主要包括子宫内膜癌和子宫肉瘤。早期发现和有效治疗对于提高生存率和生活品质至关重要。随着全球子宫内膜癌发生率的增加，对先进治疗和诊断试剂的需求也增加。透过经经阴道超音波、子宫内膜切片检查和先进影像方式等技术进行早期检测可以显着改善治疗结果。此外，手术、放射线治疗、化疗和荷尔蒙疗法等个人化治疗方法正在不断发展，以针对特定的癌症类型和阶段，改善患者的治疗效果并最大限度地减少副作用。分子诊断和生物标记测试的整合进一步提高了客製化治疗的能力，确保患者根据肿瘤的基因组成获得最有效的治疗。

科技进步如何彻底改变子宫内膜癌的治疗？

技术创新对于推进子宫内膜癌的诊断和治疗至关重要。机器人辅助手术等微创手术技术的出现缩短了恢復时间并改善了手术结果，为患者提供了创伤较小、併发症较少的选择。此外，标靶治疗和免疫疗法的发展开闢了新的治疗途径，特别是对于晚期和復发性子宫内膜癌患者。透过标靶参与癌症生长的特定分子，这些治疗方法可以实现更精确、更有效的治疗，并且比传统化疗副作用更少。在诊断方面，次世代定序仪(NGS) 和液态切片正在成为识别基因突变和即时监测治疗反应的强大工具。这些进步将使临床医生能够做出更明智的决定，根据需要调整治疗，并提供更个人化的照护。

是什么推动了子宫内膜癌先进诊断和治疗方法的采用？

子宫内膜癌的盛行率不断上升，特别是在老年族群和具有生活方式相关危险因子的人群中，导致我们正在推广先进的诊断和治疗方法。随着人们对子宫内膜癌症状和早期检测重要性的认识不断提高，越来越多的女性正在接受定期筛检，从而实现早期诊断并改善治疗结果。此外，医疗保健提供者越来越多地采用个人化医疗方法，利用基因和分子测试来帮助指导治疗决策。越来越多的研究支持这种向精准医学的转变，这些研究将特定基因突变与子宫内膜癌的治疗效果联繫起来。此外，已开发和新兴市场医疗保健支出的增加使人们能够获得先进的诊断和治疗，有助于提高存活率和患者的治疗效果。包括肿瘤科医生、放射科医生、病理学家和遗传咨询师在内的多学科护理团队的作用不断扩大，也正在加强为子宫内膜癌患者提供全面和协调的护理。

推动子宫癌药物和诊断市场成长的因素有哪些？

子宫癌治疗和诊断市场的成长受到多种因素的推动，包括诊断技术的进步、个人化治疗选择的数量增加以及全球子宫内膜癌盛行率的上升。分子诊断和生物标记主导治疗的开发正在取得进展，这些创新透过实现更有针对性和有效的治疗策略，为市场扩张做出了重大贡献。此外，人们越来越重视透过定期检查和使用先进影像技术进行早期发现，从而增加了对诊断服务的需求。人们对子宫内膜癌的认识不断提高以及及时介入的重要性也推动了患者对最先进治疗和诊断的需求。此外，已开发市场和新兴市场不断增长的医疗保健支出使得这些先进技术能够更广泛地获得，进一步推动市场成长。最后，包括标靶治疗和免疫疗法在内的不断扩大的新疗法将继续主导市场，因为这些疗法为晚期和抗药性子宫内膜癌患者带来了新的希望，预计将发挥主导作用。

受访企业范例（46家知名企业）

  • Becton, Dickinson and Company
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 比赛

简介目录
Product Code: MCP15408

Global Uterine Cancer Therapeutics and Diagnostics Market to Reach US$28.2 Billion by 2030

The global market for Uterine Cancer Therapeutics and Diagnostics estimated at US$21.4 Billion in the year 2023, is expected to reach US$28.2 Billion by 2030, growing at a CAGR of 4.0% over the analysis period 2023-2030. Endometrial Carcinomas Therapeutics and Diagnostics, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$19.0 Billion by the end of the analysis period. Growth in the Uterine Sarcomas Therapeutics and Diagnostics segment is estimated at 2.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.7 Billion While China is Forecast to Grow at 7.5% CAGR

The Uterine Cancer Therapeutics and Diagnostics market in the U.S. is estimated at US$5.7 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$6.4 Billion by the year 2030 trailing a CAGR of 7.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 4.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Global Uterine Cancer Therapeutics and Diagnostics Market - Key Trends & Drivers Summarized

Why Is Uterine Cancer Detection and Treatment So Vital?

Uterine cancer, one of the most common cancers affecting women, primarily includes endometrial cancer and uterine sarcomas. Early detection and effective treatment are critical for improving survival rates and quality of life. As the incidence of uterine cancer rises globally, the demand for advanced therapeutics and diagnostics has intensified. Early-stage detection through techniques like transvaginal ultrasound, endometrial biopsy, and advanced imaging methods can significantly improve treatment outcomes. Moreover, personalized treatment approaches, including surgery, radiation therapy, chemotherapy, and hormone therapy, have evolved to target specific cancer types and stages, improving patient outcomes and minimizing side effects. The integration of molecular diagnostics and biomarker testing has further refined the ability to tailor treatments, ensuring that patients receive the most effective therapies based on the genetic makeup of their tumors.

How Are Technological Advancements Revolutionizing Uterine Cancer Care?

Technological innovations have been pivotal in advancing both the diagnosis and treatment of uterine cancer. The advent of minimally invasive surgical techniques, such as robotic-assisted surgery, has reduced recovery times and improved surgical outcomes, offering patients less invasive options with fewer complications. Additionally, the development of targeted therapies and immunotherapies has opened new avenues for treatment, particularly for patients with advanced or recurrent uterine cancer. These therapies work by targeting specific molecules involved in cancer growth, allowing for more precise and effective treatment with fewer side effects compared to traditional chemotherapy. On the diagnostics front, next-generation sequencing (NGS) and liquid biopsies are emerging as powerful tools for identifying genetic mutations and monitoring treatment responses in real-time. These advancements enable clinicians to make more informed decisions, adjust treatments as needed, and provide more personalized care.

What Is Driving the Adoption of Advanced Diagnostics and Therapeutics in Uterine Cancer?

The increasing prevalence of uterine cancer, particularly in aging populations and those with lifestyle-related risk factors, is driving the adoption of advanced diagnostics and therapeutics. As awareness of uterine cancer symptoms and the importance of early detection grows, more women are undergoing regular screenings, leading to earlier diagnosis and better treatment outcomes. Additionally, healthcare providers are increasingly adopting personalized medicine approaches, utilizing genetic and molecular testing to guide treatment decisions. This shift towards precision medicine is supported by the growing body of research linking specific genetic mutations to treatment responses in uterine cancer. Furthermore, the rising healthcare expenditures in developed and emerging markets are enabling greater access to advanced diagnostics and treatments, contributing to improved survival rates and patient outcomes. The expanding role of multidisciplinary care teams, including oncologists, radiologists, pathologists, and genetic counselors, is also enhancing the delivery of comprehensive and coordinated care for uterine cancer patients.

What Factors Are Driving the Growth in the Uterine Cancer Therapeutics and Diagnostics Market?

The growth in the Uterine Cancer Therapeutics and Diagnostics market is driven by several factors, including advancements in diagnostic technologies, the increasing availability of personalized treatment options, and the rising prevalence of uterine cancer worldwide. The ongoing development of molecular diagnostics and biomarker-driven therapies is significantly contributing to market expansion, as these innovations allow for more targeted and effective treatment strategies. Additionally, the growing emphasis on early detection through regular screenings and the use of advanced imaging techniques is increasing the demand for diagnostic services. The rising awareness of uterine cancer and the importance of timely intervention are also driving patient demand for cutting-edge therapies and diagnostics. Furthermore, the increasing healthcare expenditure in both developed and emerging markets is enabling broader access to these advanced technologies, further fueling market growth. Finally, the expanding pipeline of new therapeutics, including targeted therapies and immunotherapies, is expected to continue driving the market as these treatments offer new hope for patients with advanced or resistant forms of uterine cancer.

Select Competitors (Total 46 Featured) -

  • Becton, Dickinson and Company
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Uterine Cancer Therapeutics and Diagnostics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Incidence of Uterine Cancer Driving Demand forg Advanced Therapeutics
    • Rising Adoption of Personalized Medicine in Cancer Treatment
    • Advancements in Genomic Testing Enhancing Early Diagnosis Capabilities
    • Growing Demand for Minimally Invasive Surgical Techniques
    • Development of Targeted Therapies Creating New Market Opportunities
    • Impact of Aging Population on Uterine Cancer Incidence
    • Increasing Investments in Cancer Research and Development
    • Adoption of AI and Machine Learning in Diagnostic Technologies
    • Rising Awareness and Screening Programs Boosting Early Detection Rates
    • Growing Demand for Combination Therapies in Cancer Treatment
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Uterine Sarcomas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Uterine Sarcomas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Uterine Sarcomas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Endometrial Carcinomas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Endometrial Carcinomas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Endometrial Carcinomas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Uterine Cancer Therapeutics and Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • JAPAN
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • CHINA
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: China 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: China 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • EUROPE
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • FRANCE
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: France 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: France 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • GERMANY
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: UK 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 74: Spain Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Spain Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Spain 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 80: Russia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Russia Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Russia 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 101: Australia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Australia Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Australia 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • INDIA
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 107: India Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: India Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: India 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 110: India Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: India 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 113: South Korea Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: South Korea Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: South Korea 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Asia-Pacific Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Asia-Pacific 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 125: Latin America Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 126: Latin America Historic Review for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Latin America 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 134: Argentina Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Argentina Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Argentina 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 140: Brazil Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Brazil Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Brazil 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 146: Mexico Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Mexico Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Mexico 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Rest of Latin America Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Rest of Latin America 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 158: Middle East Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 159: Middle East Historic Review for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Middle East 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 167: Iran Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Iran Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Iran 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 173: Israel Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Israel Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Israel 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Saudi Arabia Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Saudi Arabia 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 185: UAE Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: UAE Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: UAE 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Middle East Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Middle East 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • AFRICA
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 197: Africa Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Africa Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Africa 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030

IV. COMPETITION